Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00TUR
|
|||
| Former ID |
DNCL001602
|
|||
| Drug Name |
LY2495655
|
|||
| Indication | Disuse muscle atrophy [ICD-11: 8B61; ICD-10: R64] | Phase 2 | [1] | |
| Company |
Eli Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Growth/differentiation factor 8 (GDF-8) | Target Info | Modulator | [2] |
| Panther Pathway | TGF-beta signaling pathway | |||
| WikiPathways | Hypertrophy Model | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01505530) A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.